Which of the following statements are true regarding cefepime : a) It is a fourth generation cephalosporin b) Once a day dose is sufficient c) It possess antipseudomonal action d) Its dose should not be reduced in renal pathology e) It is a prodrug

## Core Concept
Cefepime is a cephalosporin antibiotic with a broad spectrum of activity. It is known for its effectiveness against Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. Understanding its pharmacological properties is crucial for its clinical application.

## Why the Correct Answer is Right
Cefepime is indeed **a fourth-generation cephalosporin**, which makes option (a) correct. It has a broad spectrum of activity that includes **antipseudomonal action**, making option (c) correct. Cefepime is administered **intravenously or intramuscularly** and is not considered a prodrug, which relates to option (e) being incorrect. Its pharmacokinetics allow for **once-daily dosing** in certain infections due to its long half-life, supporting option (b). However, **its dose should be adjusted in renal pathology** because cefepime is primarily excreted by the kidneys, and failure to adjust the dose can lead to accumulation and increased risk of neurotoxicity, making option (d) incorrect.

## Why Each Wrong Option is Incorrect
- **Option B:** Includes incorrect statements (d and e), making the combination incorrect.
- **Option D:** Includes an incorrect statement (d), making this combination incorrect.
- Specific to each option:
- **Option (b):** While once-daily dosing can be sufficient for certain infections, this does not exclusively make the statement about cefepime incorrect without context, but when combined with other incorrect statements, it leads to an incorrect choice.
- **Option (d):** Cefepime's dose should indeed be reduced in renal pathology to prevent toxicity, making this statement incorrect.
- **Option (e):** Cefepime is not a prodrug, which is an incorrect statement.

## Clinical Pearl / High-Yield Fact
A critical point to remember is that **cefepime's dose needs adjustment in patients with renal impairment** to prevent potential neurotoxicity. This is a high-yield fact for exams and clinical practice.

## Correct Answer: C.